This observational study is looking at how Von Willebrand Disease (VWD) affects people's lives by gathering information on bleeding events, quality of life, and the social and medical impact of these bleeds. It aims to understand the typical rates of bleeding and how VWD is currently treated. The study is open to individuals aged 16 to under 70 years old who have been diagnosed with Type 1 VWD and have bleeding symptoms. It may also include people with Type 2 or Type 3 VWD. The main goals are to measure the annual rate of bleeding events, treated bleeding events, and heavy menstrual bleeding over about 4.5 to 12.5 months. This study is not testing a new medicine, but rather collecting important information to help with future research.

Study design

This is an observational study, meaning it collects information without giving any specific treatments. It plans to include up to 200 participants with Von Willebrand Disease.

What's involved

You would participate in a screening, a baseline evaluation, and an observation period of about 4 months, with optional extension up to 12 months. This includes telemedicine check-ins every other week to monitor bleed diary entries and treatments.

Compensation

Not stated in the trial record.

Follow-up

The primary outcomes are measured over approximately 4.5 to 12.5 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.